| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, ... Blood, The Journal of the American Society of Hematology 127 (20), 2391-2405, 2016 | 10687 | 2016 |
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis … A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007 | 1177 | 2007 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1111 | 2022 |
| The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation BH Ye, G Cattoretti, Q Shen, J Zhang, N Hawe, R Waard, C Leung, ... Nature genetics 16 (2), 161-170, 1997 | 1027 | 1997 |
| European consensus on grading bone marrow fibrosis and assessment of cellularity J Thiele, HM Kvasnicka, F Facchetti, V Franco, J van Der Walt, A Orazi haematologica 90 (8), 1128-1132, 2005 | 949 | 2005 |
| Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin … TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi, RS Go, O Nielsen, ... American Society of Clinical Oncology (ASCO), 2012 | 806 | 2012 |
| MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression … S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ... Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013 | 804 | 2013 |
| The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion T Barbui, J Thiele, H Gisslinger, HM Kvasnicka, AM Vannucchi, ... Blood cancer journal 8 (2), 15, 2018 | 619 | 2018 |
| The 2015 World Health Organization classification of tumors of the thymus: continuity and changes A Marx, JKC Chan, JM Coindre, F Detterbeck, N Girard, NL Harris, ... Journal of Thoracic Oncology 10 (10), 1383-1395, 2015 | 567 | 2015 |
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for … G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ... Leukemia 22 (2), 437-438, 2008 | 553 | 2008 |
| Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management P Porcu, LD Cripe, EW Ng, S Bhatia, CM Danielson, A Orazi, LJ McCarthy Leukemia & lymphoma 39 (1-2), 1-18, 2000 | 422 | 2000 |
| Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large … C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ... Leukemia 26 (9), 2103-2113, 2012 | 401 | 2012 |
| Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP … ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ... Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012 | 392 | 2012 |
| Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus … RA Mesa, S Verstovsek, F Cervantes, G Barosi, JT Reilly, B Dupriez, ... Leukemia research 31 (6), 737-740, 2007 | 356 | 2007 |
| CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL … S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ... Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013 | 280 | 2013 |
| Hematopoietic lineage-and stage-restricted expression of the ETS oncogene family member PU. 1 R Hromas, A Orazi, RS Neiman, R Maki, C Van Beveran, J Moore, ... | 279 | 1993 |
| The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features A Orazi, U Germing Leukemia 22 (7), 1308-1319, 2008 | 260 | 2008 |
| Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. A Orazi, X Du, Z Yang, M Kashai, DA Williams Laboratory investigation; a journal of technical methods and pathology 75 (1 …, 1996 | 241 | 1996 |
| Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in … AM Gianni, M Bregni, S Siena, A Orazi, AC Stern, L Gandola, ... Journal of Clinical Oncology 8 (5), 768-778, 1990 | 230 | 1990 |
| Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms SA Wang, RP Hasserjian, PS Fox, HJ Rogers, JT Geyer, ... Blood, The Journal of the American Society of Hematology 123 (17), 2645-2651, 2014 | 224 | 2014 |
